Stem cells of fallopian tube mucosa lost their stemness characteristics under prolonged conditions

Somasundaram Indumathi1, Marappagounder Dhanasekaran2, Kaingade Pankaj3,4, Ganneru Sireesha5, Badodekar Nilaja6, Vyas Nishant7, Bhonde Ramesh8

1Department of Stem cells and Regenerative Medicine, D. Y. Patil University, Kolhapur, Maharashtra, India
2Laboratory Director, Reelabs Pvt. Ltd., Mumbai, Maharashtra, India
3Laboratory Director & Consultant Embryologist, Sunro Helix Labs, Kolhapur, Maharashtra, India
4Department of Biochemistry, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India
5Research Associate, Logical Life Sciences Pvt. Ltd. Pune, Maharashtra, India
6Research Head, Logical Life Sciences Pvt. Ltd. Pune, Maharashtra, India
7Director Research, D.Y. Patil Vidyapeet, Pimpri-Pune, Maharashtra, India
8Director Research, D.Y. Patil University, Kolhapur, Maharashtra, India

ABSTRACT

Objective: Stem cells have been identified from various adult sources, including bone marrow, adipose tissue, and placenta, to name a few. Recently, the fallopian tube has also been identified as a novel source of therapeutics. However, the ability of stem cells from the fallopian tube mucosa to retain prolonged efficacy of proliferation and differentiation is yet to be explored. This forms the basis of the present study.

Methods: Stem cells isolated from the fallopian tube mucosa were tested for their marker characterization (markers of mesenchymal, pericyte, epithelial, and cell adhesion molecules) at various passages (P1, P3, P5, P10, P15). Proliferation, differentiation (osteoblast and adipocytes), and karyotyping were also carried out at both early (P3) and late (P15) passages.

Results: Fallopian tube mucosa possesses mesenchymal stem cells, but they do not retain the ability to proliferate and differentiate beyond P15.

Conclusions: Although fallopian tube mucosal MSCs (FT-MMSCs) possess stem cell attributes, they cannot outweigh or be used in parallel to existing stem cell sources due to their inability to retain stemness characteristics beyond P15. Since FT-MMSC studies are in their infancy, further in-depth research is warranted to test whether FT-MMSCs have a use in bench to bedside applications. FT-MMSCs might be linked to tubal inflammation and fallopian tube hyperplasia, which contributes to a possible role in diagnostics and in providing insights for the betterment of womankind.

Keywords: fallopian tube mucosa, mesenchymal stem cells, proliferation, multipotent differentiation, long-term culture

INTRODUCTION

Bone marrow has been the most conventional source of stem cells in regenerative medicine (Deda et al., 2008; Prasad et al., 2012; Simari et al., 2014; Zakrezewski et al., 2019). However, there are limitations in the use of bone marrow with its seemingly low number of mesenchymal stem cells (MSC), poorer yield of nucleated cells coupled with the decline in MSC volume with advancing age, variable body mass index and tissue harvest site (Pittenger et al., 1999; Poutos et al., 2007; Stolzing et al., 2008; Rebolatto et al., 2008). These features have led scientists to explore the use of stem cells of redundant tissue sources, such as adipose tissue, for therapeutic use (Parker & Katz, 2006; Locke et al., 2009; Zhu et al., 2008; Zakrezewski et al., 2019). Besides, stem cells from female reproductive sources, such as the endometrium and fallopian tube, have gained equal interest in the last decade (Chan et al., 2004; Gargett et al., 2007; 2008; Gargett & Masuda, 2010; Dimitrov et al., 2008; Snegovskikh et al., 2014; Wang et al., 2015; Zakrezewski et al., 2019). Endometrial stem cells have been widely explored in recent years (Verdi et al., 2014; Ghobadi et al., 2015; Gargett et al., 2016; Indumathi et al., 2013; Kaingade et al., 2017). However, stem cells of fallopian tubes (hFTs), especially from the mucosa, although sharing the same embryologic origin as the uterus, have not been characterized extensively for their in-vitro attributes and functionality. Fallopian tube has the capacity to undergo dynamic endocrine-induced change during the menstrual cycle, including cell growth and regeneration (Snegovskikh et al., 2014; Wang et al., 2015). It is well documented that fallopian tube-derived cells may contribute to provide the unique environment required for fertilization, early development, and implantation onto the uterus, all of which conducive to successful reproductive outcomes (Henriksen et al., 1990; Lyons et al., 2006; Li & Winuthayanon, 2017). With these attributes, tissue fragments of human fallopian tube, which are usually discarded after surgery, may represent a potential source for regenerative medicine. Although the epithelial components of the fallopian tube are well studied (Henriksen et al., 1990; Djahanbakhch et al., 1999; Karst & Drapkin, 2012), study of their mesenchymal component is just developing in recent years in both FT-MSCs and FT-MMSCs (Jazedje et al., 2009; Wang et al., 2015). However, its wide marker characterization and retention beyond P15 on FT-MMSCs is yet to be determined.

The present study looked into whether FT-MMSCs might retain their stemness characteristics under extensive in-vitro culture and characterization.

MATERIAL AND METHODS

Sampling

The study was reviewed and approved by the members of the Institutional Ethics Committee. The samples were collected after written informed consent was obtained from the patients. Human fallopian tube biopsy specimens were collected from benign, reproducitively active women (n=10) with a mean age of 39.8±2 and a body mass index of 25.4±0.766 who were undergoing tubectomy. All samples were transported to the laboratory in a sterile...
container. The patients had not undergone exogenous hormonal treatment for at least 3 months prior to surgery.

**Isolation and culturing of MSCs**

The fallopian tube samples were processed based on our previously published paper (Indumathi et al., 2013). Briefly, the tissues were rinsed with PBS (Cat. No: TL1006, Sigma-Aldrich) supplemented with antibiotics (Cat. No: 15240-062, Invitrogen) and incubated with 0.25% trypsin (Cat. No: T0409, Sigma-Aldrich) at 37°C for 15 minutes. Later, DMEM (Cat. No: 11885084, Invitrogen) supplemented with 10% FBS (Cat. No:10270-106, Invitrogen) was added to neutralize the enzyme. Single cell suspension was further enumerated and evaluated for its cell viability using Trypan Blue staining (Cat. No: T8154, Sigma-Aldrich).

All obtained cells were plated at a density of 3.0×10^4/cm² in T-25 flasks (Cat. No: 156367, Nunc) and cultured in DMEM supplemented with 10% FBS and 1% antibiotic–antimycotic solution. Standard culture conditions of 37°C, 5% CO₂, and 95% humidity were maintained until 70–80% confluence was obtained. The cells were trypsinized and subsequently passaged upon confluence.

**Flow cytometry analysis**

The stem cells were examined for marker profiling on a flow cytometer (BD FACSArIA II). This was carried out similar to our previously published protocol (Indumathi et al., 2013). Hematopoietic markers (CD34, HLA-DR, CD14), mesenchymal stem cell markers (CD73, CD105 and CD90), cell adhesion molecules (CD49d, CD166, CD106, CD54, CD29 and CD31), perivascular markers (CD140b and CD146), and other unique markers (ABCG2 and CD117) were used for characterization. Markers and their respective fluorochromes are specified in Table 1. They were analyzed using a Becton-Dickinson FACS Aria instrument. The data was acquired from 10,000 events using the FACS Diva software.

**Intracellular staining by flow cytometry**

The cells were mixed with 500 µl of cytofix/cytoperm (Cat. No: 554722, BD Bioscience) solution to form a single cell suspension and incubated at 4°C for 20 minutes. The fixed cells were then washed with 1X wash buffer (Cat. No: 554723, BD Bioscience) at 200 g for 7 minutes. The supernatant was discarded and the cells were then resuspended with 500 µl of perm wash buffer. 1X10⁶ cells were then treated with appropriate concentrations of antibodies. All tubes were vortexed well and incubated for 45 minutes at 18°-24°C in the dark. The cells were then washed twice with perm wash buffer at 200 g for 7 minutes. The pellet was then resuspended for final flow cytometry analysis.

**Growth curve**

The growth curve analysis was carried out similar to our previous paper (Dhanasekaran et al., 2013). In short, the rate of growth of each cell population was calculated every day for nearly 2 weeks by counting the total number of cells in duplicates. The results were allotted on a log-linear scale. The growth curve characteristics were carried out in a 12-well plate in duplicates with a seeding density of 300,000 cells per plate at day 0. The population doubling time was calculated using the formula:

\[ \text{PDT} = \frac{\text{Days of exponential phase}}{\log N2 - \log N1} \log 2 \]

Where, N1 is the number of cells at the beginning of the exponential growth phase and N2 is the number of cells at the end of the exponential growth phase.

**Differentiation**

Differentiation studies were performed according to the previously published paper (Dhanasekaran et al., 2013). However, a brief protocol of each differentiation is explained below.

**Osteogenic differentiation**

Upon reaching 80–90% confluence, the complete cell culture media was replaced with osteogenic induction medium with timely replacements. Osteogenic induction media consisted of DMEM-LG, 10% FBS, 1% Antibiotic, Dexamethasone (0.1 µM) (Cat. No: D4902, Sigma), β-glycerophosphate (10 mM) (Cat. No: G-9422, Sigma) and Ascorbic acid (2 mM) (Cat. No: A4544, Sigma). Osteocytes were confirmed after 21 days of differentiation by Alizarin Red and Von Kossa staining. Stained cells were visualized using a phase contrast microscope.

**Adipogenic differentiation**

Similarly, adipogenic differentiation was promoted by differentiating the cells under the presence of adipogenic induction media containing DMEM-LG, 10% FBS, 1% Antibiotic, Dexamethasone (1µM), Isobutyl methyl xanthine (0.5 mM) (Cat. No: 15879, Sigma-Aldrich), Insulin (10 µg) (Cat. No: TCL035, HIMEDIA) and Indomethacin (200 µM) (Cat. No: 17378, Sigma-Aldrich). Adipogenic differentiation was assessed on the eighteenth day of culture by staining the MSC monolayer with triglyceride specific dye, Oil-O-Red.

**Staining**

**Von Kossa staining**

Von Kossa staining of calcium-phosphate deposits was performed according to the manufacturer’s instruction. The cells were washed 3 times with PBS before fixation with 10% formalin (Cat. No: HT50-1-2, Sigma-Aldrich) for 1 hour at room temperature. The cells were then washed 5 times with distilled water. Next, 3 ml of 2.5% silver nitrate (Cat. No: 209139, Sigma-Aldrich) were added and the cells were exposed to UV light for 45 minutes. After washing, 5% Sodium thiosulfate (Cat. No: S0764, Sigma-Aldrich) was added for 2 minutes and the cells were again washed before nuclear fast red (Cat. No: N3020, Sigma-Aldrich) staining (Dhanasekaran et al., 2013).

### Table 1. Assortment of cell surface markers and their respective fluorochromes.

| S.No. | MARKERS | FLUROCHROME |
|-------|---------|-------------|
| 1     | CD29    | PE (BD Bioscience) |
| 2     | CD166   | PE (BD Bioscience) |
| 3     | CD106   | FITC (BD Bioscience) |
| 4     | CD49d   | PE (BD Bioscience) |
| 5     | CD31    | FITC (BD Bioscience) |
| 6     | CD54    | PERCP (BD Biosciences) |
| 7     | CD34    | PE (BD Bioscience) |
| 8     | CD140b  | PE (BD Bioscience) |
| 9     | CD117   | APC (e-Biosciences) |
| 10    | CD90    | PERCP (e-Biosciences) |
| 11    | CD105   | APC (e-Biosciences) |
| 12    | CD73    | PE (BD Bioscience) |
| 13    | ABCG2   | PE (e-Biosciences) |
| 14    | CD14    | APC (e-Biosciences) |
| 15    | HLADR   | FITC (BD Bioscience) |
**Alizarin red staining**

Alizarin Red Staining identifies osteoblast differentiation by the presence of calcium deposits in cells with red dye. In short, media was removed from the culture plate and fixation with 70% alcohol was performed after the cells were washed with PBS. The cells were then incubated for 1 hour in room temperature. After 1 hour, the cells were treated with 5 ml of alizarin red working solution made form stock (Cat. No: A5533, Sigma-Aldrich) and incubated at room temperature for 30 minutes. The plates were washed twice with de-ionized water and viewed under a microscope (Dhanasekaran et al., 2013).

**Oil O Red staining**

Adipogenic differentiation was confirmed using Oil Red O staining (Cat. No: 00625, Sigma) by quantifying lipid vacuoles. The culture medium was aspirated, the cells washed with PBS and fixed with 5 ml of 10% of formalin for 10 minutes at room temperature. The solution was replaced with 5 ml of ddH2O and incubated for 1 hour at room temperature. The cells were washed with 5 ml of ddH2O followed by 5 ml of 60% isopropanol. The cells were completely dried and incubated with 3 ml of Oil Red O working solution for 10 minutes. The cells were washed with ddH2O and imaged under microscope (Dhanasekaran et al., 2013).

**Karyotyping**

Karyotyping was performed at both early and late passages to verify the maintenance of chromosomal normality according to our previous publication (Dhanasekaran et al., 2013). Standard Giemsa staining procedure was carried out; chromosome preparations were obtained from 70 to 80% confluent cells. The cells were treated with Colcemid solution (KaryoMax-Colcemid, Invitrogen) to stop microtubule formation. The mitotically arrested cells were then harvested using 0.25% trypsin–EDTA. The extracted cells were then immersed in 75 mmol/l KCl for 30 min at room temperature and were centrifuged. The supernatant was replaced with fixative (methanol: acetic acid, 3:1) and the suspension was spread over slides for observation and imaging. At least 20 metaphase spreads were analyzed. The karyotypes were imaged using a Nikon-Eclipse-90i microscope (Nikon) using cytovision software.

**Statistical Analysis**

All marker analysis from early (P3) and late passage (P15) of FT-MSCs (n=10) were shown in Mean ± SEM. The data were analyzed by using Student's t-test and p-values were calculated to determine the statistically significant variations between P3 and P15. Results were considered statistically significant when p<0.05*.

**RESULTS**

**Culturing of Stem Cells**

The stem cells from human fallopian tube samples were characterized for extensive in-vitro culturing. FT-MSCs do not retain their fibroblast-like spindle shaped morphology at later passages with elongated fibroblastic morphology (Fig. 1). Besides, cells do not grow well beyond P15.

**Cell characterization**

The markers used for characterization and their respective fluorochromes are shown in Table 1. Adherent mesenchymal stem cells from fallopian tube were characterized for various markers at different passages such as P1, P3, P5, P10, P15 (Graph 1). The expression profiles in the form of mean±SEM at early (P3) and late (P15) passages were recorded (Fig. 2). The expression profiles of MSCs were similar under extensive culturing; some of the other markers, such as CD34, CD31, SSEA4, ABCG2, and CD146, had a reduced expression in P15 as compared to P3. However, significant variations in marker expressions were found in CD49d, SSEA4, and CD117.

**Proliferative analysis**

The proliferative capacity and viability of the cultured FT-MSCs were assessed using growth curve (Fig. 3) and PDT analysis (Fig. 4). The proliferation rate of FT-MSCs was lower in the later passage as compared to the early passage condition.

**Differentiation Potential**

The differentiated cells were demonstrated by staining techniques. FT-MSCs showed a higher differentiation pattern overall, unlike the proliferative assay (Fig. 5).

**Karyotyping**

To evaluate numerical and structural chromosomal ploidy, if any, in view of long-term culture of MSC derived from FT-MSCs, the cells at both early (P3) and late passages (P15) were subjected to karyotyping and GTG banding. GTG banding results of early and late passages of karyotyping were normal (Fig. 6), indicating the retention of diploid status.

**DISCUSSION**

The discovery of stem cells led to investigations around potential sources of MSCs procured with minimally invasive techniques and limited ethical qualms (Hematti et al., 2013). The majority of stem cell applications in regenerative medicine involve stem cells isolated from bone marrow. However, the isolation of stem cells from BM is highly invasive and does not result in good yield (Faustini et al., 2010). Several sources of stem cells have been demonstrated to yield viable stem cells that retain their stemness characteristics. The isolation of MSCs from the fallopian tube (FT-MSCs) was first demonstrated in 2009 (Jazdedje et al., 2009). These cells were obtained following surgical procedures that involved fallopian tube removal. Despite the extensive knowledge gathered about fallopian tubes, the presence of stem cells in their mucosa is relatively unexplored. Both FT-MSCs and FT-MMSCs have been described as potent sources of autologous reproductive tract injury.
Graph 1. Flow cytometry data.
Comparative immunophenotyping at early and late passages. Surface markers expressed as mean±SEM.

Growth curve analysis. Growth curve analysis of FT-MSCs.

(Jazedje et al., 2009; 2012; Wang et al., 2015). The proliferative and secretory properties of FT-MMSCs have also been demonstrated to be superior to those of MSCs. Moreover, their isolation is possible via non-invasive methods, which enables easy isolation of stem cells with limited ethical qualms. Despite these advantages, the ability of FT-MMSCs to retain their stemness under long-term culture conditions needs to be assessed in order to ascertain their therapeutic potential in regenerative medicine.

Our study found that FT-MMSCs possess wide marker characteristics throughout passages such as P3, P5, P10 and P15 as compared to stem cells conventionally procured from bone marrow (Chan et al., 2004; Gargett...
Figure 4. Population doubling time. PDT of FT-MMSCs at early and late passage.

Figure 5. Differentiation study. A,F. Undifferentiated cell; B,E. Adipocyte differentiation (P3); C,D. Osteoblast differentiation at early and late passage, respectively.
et al., 2008; Gargett & Masuda, 2010; Dimitrov et al., 2008). Despite similarities in their marker characteristics, a few markers such as CD49d, CD117 and SSEA4 showed a significant difference in their expression pattern at P15. Besides, evident change in morphology at P15 coupled with reduced growth potential was demonstrated. Morphologically, the cells changed their shape as demonstrated in Figure 1, became non-adherent, and lost their ability to grow beyond P15. However, no karyotype changes were noted at P15. The major risks associated with the use of MSCs are malignant transformation, GvHD, and aging of the in vitro differentiated stem cell population (Tong et al., 2021). In order to prevent the risks associated with stem cells in regenerative medicine, the definition of their attributes and efficacy up to specific passages in vitro prior to administration is required. In addition, the differentiation potential, expression of surface markers, and chromosomal ploidy also need to be assessed to ensure they can be used. Thus, overall, due to changes in morphology, non-adherent and reduced growth potential beyond P15, it was postulated that FT-MMSCs could not outweigh the existing potent sources of MSCs such as adipose tissue and bone marrow (Dhanasekaran et al., 2012; 2013) in regenerative medicine applications.

Nevertheless, FT-MMSCs retain their stemness potential in early passages, and might therefore be used in treating reproductive tract injuries and other tubal infections. The high differentiation potential observed in our study was similar to the potential reported in studies carried out by Wang et al. (2015). Therefore, this study might provide input for researchers working on the potential uses of these stem cells in treating bone diseases, especially osteoporosis, a common condition in postmenopausal women. Previous findings corroborate this application (Jazedje et al., 2012; Wang et al., 2015) and highlight the use of FT-MSCs and FT-MMSCs in bone-related diseases.

Another interesting avenue that can be explored is the high levels of expression of markers of pericytes in the endometrium (Indumathi et al., 2013; Kaingade et al., 2017) and lower expression levels in FT-MMSCs, despite their common origins, in studies designed to probe into the roles of stem cells and pericytes in fallopian tubes with normal physiology and disease. This study also opens the door to hypotheses around the potential role dysfunctional FT-MSCs and FT-MMSCs have in tubal infections or tubal hyperplasia and injury.

Further studies need to be conducted to determine the effect of external growth factors on the stemness of FT-MMSCs. Also, the effects of FT-MMSCs on immunomodulation are of paramount importance in regenerative medicine and tissue injury applications. Overall, we recommend the use of FT-MMSCs in stem cell applications that require a high differentiation potential. Since the cells were able to maintain stemness in early passages, they might be utilized in wound healing of reproductive tract injuries and in the treatment of tubal infections by autologous transplantation (Fig. 7). The mucosa might serve as an ideal source for the isolation of mesenchymal stem cells owing to minimal invasiveness and rapid proliferation.

CONCLUSIONS

Since the fallopian tubes play a major role in the reproductive phases of women, understanding the stem cells procured from this source becomes imperative. Thus, this study was carried out to understand whether FT-MMSCs were able to retain stemness characteristics under long-term culture. Although they did not retain their characteristics as stem cells from other potent sources do, FT-MMSCs might be an alternative element in the treatment of reproductive tract injuries and other tubal infections, although further extensive research on the subject is needed. Besides, as reported earlier, the functionality of FT-MMSCs in fertility and sterility and other pathological reproductive complications is a worthwhile investigation for the betterment of woman-kind, which might lead more successful reproductive outcomes.

ACKNOWLEDGMENTS

We thank all the participants who participated in this study.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

Corresponding author:
Somasundaram Indumathi
Department of Stem cell and Regenerative Medicine
D.Y. Patil University
Kolhapur, Maharashtra, India.
E-mail: drindumathisomasundaram@gmail.com
Figure 7. Graphical summary of the study and potential applications: The key findings of the study: alteration of stemness characteristics of fallopian tube mucosal mesenchymal stem cells (FT-MMSCs), immunomodulatory properties, and role in tissue repair have been graphically summarized in the figure. The potential applications of FT-MMSCs have also been mentioned.

REFERENCES

Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod. 2004;70:1738-50. PMID: 14766732 DOI: 10.1095/biolreprod.103.024109

Deda H, Inci MC, Kürekçi AE, Kayihan K, Ozgün E, Ustünsoy GE, Kocabay S. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy. 2008;10:565-74. PMID: 18615345 DOI: 10.1080/14653240802241797

Dhanasekaran M, Indumathi S, Rashmi M, Rajkumar JS, Sudarsanam D. Unravelling the retention of proliferation and differentiation potency in extensive culture of human subcutaneous fat-derived mesenchymal stem cells in different media. Cell Prolif. 2012;45:516-26. PMID: 23106299 DOI: 10.1111/j.1365-2184.2012.00843.x

Dhanasekaran M, Indumathi S, Lissa RP, Harikrishnan R, Rajkumar JS, Sudarsanam D. A comprehensive study on optimization of proliferation and differentiation potency of bone marrow derived mesenchymal stem cells under prolonged culture condition. Cytotechnology. 2013;65:187-97. PMID: 22729554 DOI: 10.1007/s10616-012-9471-0

Djahanbakhch O, Saridogan E, Kervancioglu ME, Mahmood T, Li L, Grudzinskas JG. Secretory function of the Fallopian tube epithelial cells in vitro: A review. Placenta. 1999;20:87-104. DOI: 10.1016/S0143-4004(99)80008-3

Dimitrov R, Timeva T, Kyurkchiev D, Stamenova M, Shterev A, Kostova P, Zlatkov V, Khayov I, Kyurkchiev S. Characterization of clonogenic stromal cells isolated from human endometrium. Reproduction. 2008;135:551-8. PMID: 18367513 DOI: 10.1530/REP-07-0428

Faustini M, Bucco M, Chlapanidas T, Luccconi G, Marazzi M, Tosca MC, Gaetani P, Klinger M, Villani S, Ferretti VV, Vigo D, Torre ML. Nonexpanded mesenchymal stem cells for regenerative medicine: yield in stromal vascular fraction from adipose tissues. Tissue Eng Part C Methods. 2010;16:1515-21. PMID: 20486782 DOI: 10.1089/ten.tec.2010.0214

Gargett CE, Chan RW, Schwab KE. Endometrial stem cells. Curr Opin Obstet Gynecol. 2007;19:377-83. PMID: 17625422 DOI: 10.1097/GCO.0b013e328223a5c6

Gargett CE, Chan RW, Schwab KE. Hormone and growth factor signaling in endometrial renewal: role of stem/progenitor cells. Mol Cell Endocrinol. 2008;288:22-9. PMID: 18403104 DOI: 10.1016/j.mce.2008.02.026
Gargett CE, Masuda H. Adult stem cells in the endometrium. Mol Hum Reprod. 2010;16:818-34. PMID: 20627991 DOI: 10.1093/molehr/gaq061

Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Hum Reprod Update. 2016;22:137-63. PMID: 26552890 DOI: 10.1093/humupd/dmv051

Ghobadi F, Mehrabani D, Mehrabani G. Regenerative potential of endometrial stem cells: a mini review. World J Plast Surg. 2015;4:3-8. PMID: 25606470

Hematti P, Kim J, Stein AP, Kaufman D. Potential role of mesenchymal stromal cells in pancreatic islet transplantation. Transplant Rev (Orlando). 2013;27:21-9. PMID: 23290684 DOI: 10.1016/j.trre.2012.11.003

Henriksen T, Tanbo T, Abyholm T, Oppedal BR, Claussen OP, Hovig T. Epithelial cells from human fallopian tube in culture. Hum Reprod. 1990;5:25-31. PMID: 2182659 DOI: 10.1093/oxfordjournals.humrep.a137034

Indumathi S, Harikrishnan R, Rajkumar JS, Sudaransan D, Dhanasekaran M. Prospective biomarkers of stem cells of human endometrium and fallopian tube compared with bone marrow. Cell Tissue Res. 2013;352:537-49. PMID: 23460308 DOI: 10.1007/s00441-013-1582-1

Jazedje T, Perin PM, Czeresnia CE, Maluf M, Halpern S, Secco M, Bueno DF, Vieira NM, Zucconi E, Zatz M. Human fallopian tube: a new source of multipotent adult mesenchymal stem cells. J Transl Med. 2009;7:46. PMID: 19538712 DOI: 10.1186/1479-5876-7-46

Jazedje T, Bueno DF, Caetana H, Czeresnia CE, Perin PM, Halpern S, Maluf M, Evangelista LP, Nisenbaum MG, Martins MT, Passos-Bueno MR, Zatz M. Human fallopian tube mesenchymal stromal cells enhance bone regeneration in a xenotransplanted model. Stem Cell Rev Rep. 2012;8:355-62. PMID: 21744049 DOI: 10.1007/s12015-011-9297-8

Kaiagade P, Nikam A, Kulkarni S, Somasundaram I. Marker profiles of human endometrial stem cells at various passages cultured in-vitro. J Stem Cell Res Ther. 2017;2:5-10.

Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc. 2012;7:1755-64. PMID: 22936217 DOI: 10.1038/nprot.2012.097

Li S, Winuthayanon W. Oviduct: roles in fertilization and early embryo development. J Endocrinol. 2017;232:R1-R26. PMID: 27875265 DOI: 10.1530/JOE-16-0302

Locke M, Windsor J, Dunbar PR. Human adipose-derived stem cells: isolation, characterization and applications in surgery. ANZ J Surg. 2009;79:235-44. PMID: 19432707 DOI: 10.1111/j.1445-2197.2009.04852.x

Lyons RA, Saridogan E, Djahanbakchch O. The reproductive significance of human Fallopian tube cilia. Hum Reprod Update. 2006;12:363-72. PMID: 16565155 DOI: 10.1093/humupd/dml012

Parker AM, Katz AJ. Adipose-derived stem cells for the regeneration of damaged tissues. Expert Opin Biol Ther. 2006;6:567-78. PMID: 16706604 DOI: 10.1517/14712598.6.6.567

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7. PMID: 10102814 DOI: 10.1126/science.284.5411.143

Pountos I, Corscadden D, Emery P, Giannoudis PV. Mesenchymal stem cell tissue engineering: techniques for isolation, expansion and application. Injury. 2007;38:523-33. PMID: 18224734 DOI: 10.1016/S0020-1383(08)70006-8

Prasad K, Mohanty S, Bhatia R, Srivastava MV, Garg A, Srivastava A, Goyal V, Tripathi M, Kumar A, Bal C, Vij A, Mishra NK. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res. 2012;136:221-8. PMID: 22960888

Rebelatto CK, Aguilier AM, Moretão MP, Senegaglia AC, Hansen P, Barchiki F, Oliveira J, Martins J, Kuligovski C, Mansur F, Christofis A, Amaral VF, Brofman PS, Goldenberg S, Nakao LS, Correa A. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood). 2008;233:901-13. PMID: 18445775 DOI: 10.3181/0712-RM-356

Simari RD, Pepine CJ, Traverse JH, Henry TD, Bolli R, Spoon DB, Yeh E, Hare JM, Schulman IH, Anderson RD, Lambert C, Sayre SL, Taylor DA, Ebert RF, Mayé LA. Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. Circ Res. 2014;114:1564-8. PMID: 24812350 DOI: 10.1161/CIRCRESAHA.114.303720

Snegovskikh V, Mutlu L, Massasa E, Taylor HS. Identification of putative fallopian tube stem cells. Reprod Sci. 2014;21:1460-4. PMID: 25305130 DOI: 10.1177/1933719114553448

Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129:163-73. PMID: 18241911 DOI: 10.1016/j.mad.2007.12.002

Tong Y, Zuo J, Yue D. Application Prospects of Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia and the Challenges Encountered. Biomed Res Int. 2021;2021:9983664. PMID: 33997051 DOI: 10.1155/2021/9983664

Verdi J, Tan A, Shoae-Hassani A, Seifalian AM. Endometrial stem cells in regenerative medicine. J Biol Eng. 2014;8:20. PMID: 25097665 DOI: 10.1186/1754-1611-8-20

Wang J, Zhao Y, Wu X, Yin S, Chuai Y, Wang A. The utility of human fallopian tube mucosa as a novel source of multipotent stem cells for the treatment of autologous reproductive tract injury. Stem Cell Res Ther. 2015;6:98. PMID: 25994820 DOI: 10.1186/s13287-015-0094-1
Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res Ther. 2019;10:68. PMID: 30808416 DOI: 10.1186/s13287-019-1165-5

Zhu Y, Liu T, Song K, Fan X, Ma X, Cui Z. Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct. 2008;26:664-75. PMID: 18636461 DOI: 10.1002/cbf.1488